Lytix Biopharma presenting at major investor conferences in London and Stockholm in November
Oslo, 8 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that Dr Øystein Rekdal, CEO, will deliver oral presentations to institutional investors in London at the LSX Inv€$tival Showcase on the 13th of November, and attend the Jefferies Healthcare Conference on the 14th -16th November.
Investors interested in meeting should get in contact through the event partnering system or through the IR team.
